CAC score: coronary artery calcium as the most accurate heart screening test

Introduction: a test that sees plaque instead of calculating risk

When people talk about "assessing myocardial infarction risk," they usually mean risk scores — ASCVD, SCORE2, Framingham. These scores combine age, sex, blood pressure, LDL, diabetes, and smoking, then output the probability of an event over 10 years. This is a useful tool, but it has a fundamental limitation: it does not see your own blood vessel. It averages the population.

CAC score (coronary artery calcium) is a low-dose non-contrast computed tomography scan of the chest that measures coronary artery calcification using the Agatston scale. It is direct visualization of atherosclerotic plaque, not a probability.

Key idea of the md_pereligyn protocol: LDL and ApoB tell us what pressure is pushing into the vessel wall. CAC shows what has already accumulated in the wall itself. These are two different snapshots — past damage (CAC) and future pressure (ApoB / Lp(a)) — and they are used together, not instead of each other.

After 10–20 years of elevated ApoB or hypertension, plaque calcifies. CT can see it. The ASCVD score cannot. That is why CAC can reclassify a patient — avoid a statin in someone who was "borderline" by risk score, or start aggressive therapy where the lipid panel looked reassuring.

🌀

What the Agatston score measures

The Agatston score sums the volume and density of calcified lesions across all coronary arteries. Calcification is a marker of mature atherosclerotic plaque. Early "soft" plaque (lipid core, fibroatheroma) may not be calcified, yet it is often the plaque that ruptures and causes myocardial infarction. Therefore, CAC sees more of the "accumulated" risk than the "acute" risk.

The method has important characteristics:

▸Low radiation dose — 0.5–1.5 mSv, equivalent to annual natural background radiation. ▸No contrast — no kidney burden, no allergic reactions. ▸High reproducibility — interobserver variability <10%. ▸10–15-year prognosis — not a one-time snapshot, but a long-term predictor. ▸Cost 100–250 USD in most countries — more accessible than angiography.

🌀

Agatston score categories

The score is divided into four clinically meaningful categories, each with its own strategy.

•Score 0 — Power of zero. No calcified plaque. This is the strongest negative predictor in people older than 45 years: 10-year myocardial infarction risk below 1% (Greenland P, Circulation 2019, PMID 30879355^[1]). It does not mean "zero risk forever" — in younger people and with high Lp(a), plaque may not yet have had time to calcify. Repeat in 5–7 years, especially with a family history. •Score 1–99 — mild calcification. Atherosclerosis has started but is not yet mature. Intensify prevention — lifestyle, omega-3, ApoB and blood pressure control. A statin is not prescribed by default; the decision is individualized. •Score 100–399 — moderate calcification. Equivalent to intermediate-high risk. Statin therapy is indicated for most patients, with aggressive LDL control to <70 mg/dL and discussion of aspirin if there are no contraindications. •Score ≥400 — high risk. In event prognosis, this is equivalent to established coronary artery disease (Detrano R, NEJM 2008, PMID 18367736^[2]). Aggressive lipid-lowering (statin + ezetimibe ± PCSK9), blood pressure control, and discussion of functional testing (stress test, CT angiography).

Each doubling of CAC above 100 means a doubling of risk. Score 800 is not simply Score 400 "×2 in the wrong direction" — it is exponentially worse.

🌀

Who should have the test

CAC provides the most information not for everyone, but for a clearly defined subgroup — people in whom the statin decision is "50/50."

▸Age 40–75 years + intermediate ASCVD risk (5–20% over 10 years) — to refine the statin decision. This is the main indication supported by the 2019 ACC/AHA guidelines. ▸Family history of early myocardial infarction (father < 55 years, mother < 65 years) — regardless of lipid levels. ▸Perimenopausal and postmenopausal women with borderline lipids — in women, the ASCVD score often underestimates risk. ▸Patients who do not want to take a statin despite moderate lipid risk — CAC = 0 provides a justified reason to defer; CAC > 100 provides a reason to "start after all." ▸Patients with metabolic syndrome, prediabetes, PCOS — for vascular age stratification. ▸Lp(a) > 50 mg/dL — CAC helps show how much of the genetic risk has already been realized.

🌀

Who does NOT need CAC

▸Age < 40 years without family history — calcification has not yet had time to develop, so the result may be falsely reassuring. ApoB and Lp(a) work better in younger people. ▸Already established coronary artery disease, prior myocardial infarction, previous stenting/CABG — a statin is indicated regardless of the score, and the decision has already been made. ▸Pregnancy — radiation exposure, an absolute contraindication. ▸Patients with CAC > 400 in the recent past — repeating it every year is pointless unless the treatment plan is changing. ▸End-stage systemic disease of any kind — the priority is different.

🌀

What CAC does NOT replace

The most common mistake is treating CAC as a universal "one test for everything." It is not. CAC sees mature calcified plaque. It does not see:

▸Lp(a) — a genetic risk factor that increases LDL atherogenicity and promotes aortic valve calcification. It is measured once as a blood test. More detail in the article Lp(a) — genetic cardiovascular risk factor. ▸ApoB — the number of atherogenic particles in plasma. LDL shows cholesterol within these particles; ApoB shows their number. ApoB predicts risk more accurately, especially in metabolic syndrome. ▸hsCRP — a marker of vascular inflammation and plaque instability. Plaque can be small but "hot." ▸Endothelial dysfunction — an early stage of vascular injury that precedes plaque by 10–20 years. See Endothelium: foundation of vascular health. ▸Soft (non-calcified) plaque — only contrast-enhanced CT angiography or IVUS can see it.

Principle: CAC is a snapshot of past damage. ApoB and Lp(a) are a snapshot of future pressure. hsCRP is a snapshot of current inflammation. They are used together.

🌀

Holistic protocol for different CAC levels

### 1. CAC = 0

▸Confirm that there are no other high-risk markers: Lp(a), family history, ApoB > 100 mg/dL, hsCRP > 2 mg/L. ▸Support: Mediterranean / DASH diet, movement 150+ min/week, omega-3 index >8%, vitamin D 50–80 ng/mL, sleep control. ▸Do not prescribe a statin by default if overall risk is low and there is no familial hypercholesterolemia. ▸Repeat in 5–7 years (earlier if younger than 50 years).

### 2. CAC 1–99

▸Intensify prevention: ApoB target <80 mg/dL, blood pressure <120/80, omega-3 index >8%, insulin sensitivity index (HOMA-IR <1.5). ▸Nutraceuticals: omega-3 EPA+DHA 2 g/day, magnesium (glycinate) 400 mg, vitamin D3 + K2 (MK-7) 100–200 μg, CoQ10 100–200 mg, pomegranate extract 250–500 mg for the endothelium. ▸Lifestyle: smoking cessation (absolute priority), 7–8 h of sleep, strength + aerobic training. ▸Statin decision: individualized, based on the totality of factors. In some patients, it is reasonable to start a low-dose statin (rosuvastatin 5–10 mg).

### 3. CAC 100–399

▸Statin therapy for most: rosuvastatin 10–20 mg or atorvastatin 20–40 mg with a target ApoB <70 mg/dL / LDL <70 mg/dL. ▸Blood pressure control to <130/80, ideally 120/80 when possible. ▸HbA1c <5.7%, fasting insulin <8 μIU/mL. ▸Aspirin 75–100 mg — discussed individually if bleeding risk is not increased. ▸Full carotid artery evaluation (internal carotid artery ultrasound), functional stress test if symptomatic. ▸Holistic support: omega-3 2–4 g/day, CoQ10 200 mg (especially on a statin), polyphenols (pomegranate, cocoa, EGCG), magnesium 400 mg.

### 4. CAC ≥ 400

▸Aggressive lipid-lowering: statin + ezetimibe; if ApoB does not reach the target <65 mg/dL — add a PCSK9 inhibitor (alirocumab, evolocumab). ▸Stress test and/or CT angiography to identify a functionally significant stenotic zone. ▸Cardiologist: lifelong follow-up, discussion of revascularization if ischemia is present. ▸Control of all modifiable factors: smoking — complete cessation, blood pressure, glycemia, weight, sleep, stress. ▸Holistic support: the same nutraceuticals as for CAC 100–399, plus emphasis on the endothelial protocol (L-arginine 3–6 g, citrulline 3 g, BH4 regeneration with polyphenols).

🌀

What does NOT work

▸CAC in a patient <40 years without family history — a zero result is not reassuring, because plaque has not yet had time to calcify. Lp(a) and ApoB are better. ▸Repeating CAC annually — changes accumulate slowly; an informative interval is 3–5 years (1 year when selecting aggressive therapy). ▸Using CAC as a replacement for the lipid panel — these are two different snapshots. Score 0 with ApoB 130 mg/dL and Lp(a) 100 nmol/L still means high risk; the plaque simply has not calcified yet. ▸Ignoring symptoms when CAC = 0 — typical angina requires evaluation regardless of the score. Score 0 does not exclude rupture of a young soft plaque. ▸Prescribing a statin based only on CAC without assessing overall risk — in a patient with CAC 50 and ApoB 60 mg/dL plus excellent lifestyle, the statin decision is individualized.

🌀

When to seek care

▸Age 40–75 years with intermediate ASCVD risk (5–20% over 10 years) ▸Family history of coronary artery disease / myocardial infarction / stroke before age 60 years (men <55, women <65) ▸Borderline lipids + uncertainty about a statin ▸Metabolic syndrome, prediabetes, type 2 diabetes ▸Lp(a) > 50 mg/dL (>125 nmol/L) ▸hsCRP > 2 mg/L on repeated testing ▸Desire for an objective assessment of vascular age

I perform full vascular stratification (CAC, Lp(a), ApoB, omega-3 index, hsCRP, HOMA-IR) and create a personalized plan — which tests, in what order, and which holistic protocol fits your risk level.

🌀

Conclusion

CAC score is the most accurate single screening test for cardiology risk in an asymptomatic adult. It does not replace the lipid panel and is not the same as "having the full workup," but it reclassifies patients more accurately than any risk score. Score 0 provides a justified opportunity to work through prevention; Score > 400 justifies aggressive therapy.

The combination of CAC + ApoB + Lp(a) + hsCRP + omega-3 index gives the physician four different cross-sections of the same process: accumulated damage, current pressure, genetic background, and inflammation. This quartet is the basis of modern cardiovascular prevention, and it is exactly what the md_pereligyn protocol places above the ASCVD score.

Treat the vessel, not its complications.

🌀

Sources

▸Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med* 2008;358:1336–1345. PMID 18367736 ▸Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. *Circulation* 2019;72:434–447. PMID 30879355 ▸Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. *JAMA* 2010;303:1610–1616. PMID 20424251 ▸Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people. *J Am Coll Cardiol* 2019;74:380–388. PMID 31466618 ▸Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. *Circulation* 2019;140:e596–e646. PMID 30879355

Related articles: Endothelium: foundation of vascular health, Cholesterol without statins.

🌀

FAQ

Is the radiation from CAC dangerous? The dose is 0.5–1.5 mSv — equivalent to annual natural background radiation or 2–3 intercontinental flights. For screening once every 5–7 years, this is safe. Women of reproductive age should discuss it with a physician; it is contraindicated in pregnancy.

If my CAC = 0, can I forget about cholesterol? No. Score 0 does not exclude soft non-calcified plaque and does not cancel genetic risk (Lp(a)). If ApoB > 100 mg/dL or Lp(a) > 50 mg/dL — continue prevention. Repeat CAC in 5–7 years.

Can already detected CAC be "reset to zero"? Calcification is irreversible — calcified deposits cannot be "dissolved." But progression can be stopped and plaque stabilized: the goal is not to "zero out the score," but to prevent it from growing faster than 10–15% per year. With a statin + holistic protocol, this is achievable.

Why ApoB if CAC has already been done? CAC is a snapshot of the past; ApoB is the pressure pushing toward new plaque right now. Controlling ApoB after CAC means preventing plaque growth. Without ApoB, you know what happened before, but not where you are going.

How soon should CAC be repeated? With CAC = 0 — in 5–7 years (earlier in younger people). With CAC 1–99 — in 3–5 years. With CAC 100–399 — in 3 years or after a therapy change. With CAC > 400 — repeat testing is usually unnecessary; the focus is functional diagnostics and ApoB control.

*This article is informational and does not replace medical consultation. Before starting any nutraceuticals, changing medication therapy, or undergoing diagnostic procedures, discuss the plan with your treating physician.*

🌀

CAC distribution across sex and ethnicity: why the same Agatston number means different things

The four Agatston categories (0, 1–99, 100–399, ≥400) in the article are absolute thresholds, but the underlying epidemiology is not uniform across the population. The Multi-Ethnic Study of Atherosclerosis (MESA), which enrolled 6,814 adults aged 45–84 years from four ethnic groups, demonstrated that for any given age and sex, calcium burden differs substantially between Whites, Blacks, Hispanics, and Chinese Americans, with Whites and Chinese carrying the highest prevalence of detectable calcium and Blacks the lowest PMID: 16157765. Because of this, an Agatston of 100 in a 55-year-old White male places him near the 50th percentile, while the same score in a 55-year-old Black female of the same age places her above the 90th percentile — and percentile rank, not the raw number, is what maps most cleanly to relative risk.

This is why modern reporting from accredited centers includes both the absolute Agatston score and the MESA percentile (available through the free MESA CAC calculator at mesa-nhlbi.org). A score above the 75th percentile for age, sex, and ethnicity is treated as elevated even when the absolute number is modest. Conversely, a CAC of 200 in an 80-year-old White male sits below the 50th percentile and may not warrant the same intensification that the same score would prompt in a 50-year-old.

Sex differences are equally important. Women develop calcified plaque approximately a decade later than men. In MESA, the prevalence of CAC > 0 in women under 55 was below 30%, while in men of the same age it exceeded 50% PMID: 16157765. After menopause, the gap narrows, and CAC progression accelerates — a pattern consistent with the loss of estrogen-mediated endothelial protection. As a result, a CAC of 50 in a 48-year-old woman carries more reclassification weight than the same score in a 48-year-old man, because the underlying prevalence is lower and the relative deviation is larger.

The practical implications:

• Always interpret CAC alongside age-sex-ethnicity percentile, not as a free-standing number. - In women, a CAC of 1–99 in the perimenopausal window often justifies more aggressive prevention than the same score in a 60-year-old woman. - In Black patients, a non-zero CAC has particularly high prognostic weight because the prevalence is lower at any given age — the score is a stronger "positive" signal. - In South Asian patients (not represented in MESA), the available cohort data suggest a calcium-light, lipid-heavy phenotype: ApoB and Lp(a) carry more weight, and a low CAC does not exclude high atherosclerotic burden [PMID: 28935033](https://pubmed.ncbi.nlm.nih.gov/28935033/).

🌀

Quantifying CAC progression: what counts as accelerated, and how it is calculated

The article notes that progression above 10–15% per year is the treatment threshold but does not define how progression is measured. The Agatston score is heteroscedastic — its variance grows with the baseline — so simple year-over-year subtraction overestimates true change in patients with high baseline scores and underestimates it in patients near zero. The validated approach is the square-root method: progression is defined as a difference in √CAC of ≥2.5 between scans, which corresponds to clinically meaningful plaque accumulation independent of baseline burden PMID: 19797751.

Using this metric, the MESA progression substudy followed 5,756 participants over a median 7.6 years and showed that the rate of CAC change was an independent predictor of incident coronary heart disease and all-cause mortality, even after adjustment for baseline CAC and traditional risk factors PMID: 23036823. Patients in the highest tertile of annualized progression had a hazard ratio of approximately 1.5 for coronary events versus those in the lowest tertile with comparable baseline scores. In other words, two patients with the same starting Agatston of 150 do not carry the same five-year risk if one is progressing at 5% per year and the other at 25%.

Typical natural-history progression rates without intensified prevention:

• Baseline CAC = 0: approximately 25% will develop detectable calcium within 5 years; the median time to conversion is 6–8 years [PMID: 25770314](https://pubmed.ncbi.nlm.nih.gov/25770314/). - Baseline CAC 1–99: annualized progression of 15–25% is typical. - Baseline CAC 100–399: annualized progression of 12–18%. - Baseline CAC ≥ 400: absolute increments are large but proportionally smaller (8–15%).

Acceleration above these bands — for example, doubling within 2 years or annualized growth above 30% in a treated patient — is a signal that the underlying drivers (LDL/ApoB, blood pressure, glycemia, inflammation, Lp(a)) are not adequately controlled and that escalation, including PCSK9 inhibition or functional testing, should be considered PMID: 29161116. Progression alone, independent of symptoms, is not an indication for revascularization, but it is a robust trigger for therapeutic intensification.

The reasonable interval for repeat scanning is 3–5 years for stable patients and 1–2 years when the treatment plan is actively being modified — long enough to exceed scan-to-scan variability (interscan reproducibility is approximately 10–15%) but short enough to detect meaningful change.

🌀

When to escalate from CAC to CT coronary angiography (CCTA)

The article correctly states that CAC does not see non-calcified plaque. CCTA does. These are two related but distinct tests, and conflating them is a common source of error. CAC is a non-contrast scan that detects only calcified deposits; CCTA uses intravenous iodinated contrast and higher radiation (3–10 mSv versus 0.5–1.5 mSv for CAC) to visualize the lumen, wall, and full plaque composition, including soft fibrofatty plaque, mixed plaque, and stenosis severity.

Large randomized trials of CCTA-guided versus standard care in patients with stable chest pain have demonstrated reductions in coronary death and non-fatal myocardial infarction in the CCTA arm, driven primarily by intensified preventive therapy in patients whose scans revealed non-obstructive but extensive plaque. Anatomic testing with CCTA has been shown non-inferior to functional stress testing for symptomatic patients and identifies more patients who benefit from statin initiation. A 2017 meta-analysis pooling CCTA outcome data confirmed that the presence of any non-obstructive plaque on CCTA carries prognostic weight comparable to traditional risk-factor burden, and that absence of plaque on CCTA is one of the strongest negative predictors available in cardiology PMID: 27037982.

Practical escalation rules:

• CAC = 0 + asymptomatic patient: CCTA adds little; the negative predictive value of CAC alone is already ~99% for obstructive disease over 5 years. - CAC = 0 + typical anginal symptoms or strong family history of premature CAD: CCTA is reasonable. Soft plaque rupture can cause infarction with a zero score, particularly in younger patients and those with elevated Lp(a) [PMID: 32466879](https://pubmed.ncbi.nlm.nih.gov/32466879/). - CAC 1–99 + asymptomatic: usually no need for CCTA; treat the calcium signal as confirmation of subclinical atherosclerosis and intensify prevention. - CAC ≥ 400 or rapid progression: CCTA or functional stress testing is reasonable to identify a flow-limiting lesion that may justify revascularization. - Atypical chest pain + intermediate pre-test probability: CCTA outperforms exercise ECG for ruling out significant disease [PMID: 25234519](https://pubmed.ncbi.nlm.nih.gov/25234519/).

CAC is a screening test; CCTA is a diagnostic test. The decision to escalate depends on symptoms, score, progression, and the question being asked.

🌀

CAC progression on statin therapy: the paradox patients ask about

A frequent and underappreciated clinical scenario: a patient starts a statin after a CAC of 200, repeats the scan three years later, and the score has risen to 280. The patient asks whether the drug failed. It did not. Statins paradoxically increase the calcified component of plaque while reducing total plaque volume and event risk — a well-replicated finding that confuses both patients and physicians who are not familiar with the mechanism PMID: 25770314.

The biology: statins shift plaque composition from soft, lipid-rich, rupture-prone lesions toward dense, calcified, stable lesions. Calcification is part of plaque stabilization. Intravascular ultrasound and CCTA studies of statin-treated patients consistently show reduction in total atheroma volume but increase in the calcified fraction PMID: 25770314. The CAC score, which measures only the calcified component, therefore rises even as the underlying disease becomes less dangerous.

The clinical implication is that absolute Agatston change in a patient already on a high-intensity statin is not interpretable in the same way as change in an untreated patient. The same 80-point rise that would signal failed prevention in an untreated patient may represent successful plaque stabilization in a treated one. What matters in the treated patient is:

• The trajectory of ApoB and LDL — are they at target (<70 or <55 mg/dL depending on risk)? - The density of new calcium (which can be quantified separately) — high-density calcium is more stable than spotty mixed calcification [PMID: 33309175](https://pubmed.ncbi.nlm.nih.gov/33309175/). - Symptoms — anginal symptoms or exercise intolerance, regardless of CAC change, mandate functional evaluation. - Lp(a), hsCRP, and metabolic markers — if these are uncontrolled, the underlying driver is not addressed.

For untreated patients, rising CAC is a direct signal of disease progression. For treated patients, it is a signal that must be interpreted in context — and a rising score on a statin is not a reason to stop therapy. The clinical trial endpoint is events, not the calcium number. Patients should be informed of this paradox before they undergo a repeat scan, because the conversation about "my number went up despite the medication" is one of the most predictable points of treatment non-adherence.